Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Impact of comprehensive hospice palliative care on end-of-life care: a propensity-score-matched retrospective observational study.

Conlon MSC, Caswell JM, Knight A, Ballantyne B, Santi SA, Meigs ML, Earle CC, Hartman M.

CMAJ Open. 2019 Apr 4;7(2):E197-E202. doi: 10.9778/cmajo.20180148. Print 2019 Apr-Jun.

2.

Access to Palliative Care for Cancer Patients Living in a Northern and Rural Environment in Ontario, Canada: The Effects of Geographic Region and Rurality on End-of-Life Care in a Population-Based Decedent Cancer Cohort.

Conlon MS, Caswell JM, Santi SA, Ballantyne B, Meigs ML, Knight A, Earle CC, Hartman M.

Clin Med Insights Oncol. 2019 Feb 14;13:1179554919829500. doi: 10.1177/1179554919829500. eCollection 2019.

3.

Outcome Measures for Central Nervous System Evaluation in Myotonic Dystrophy Type 1 May Be Confounded by Deficits in Motor Function or Insight.

Hamilton MJ, McLean J, Cumming S, Ballantyne B, McGhie J, Jampana R, Longman C, Evans JJ, Monckton DG, Farrugia ME.

Front Neurol. 2018 Oct 2;9:780. doi: 10.3389/fneur.2018.00780. eCollection 2018.

4.

Early Versus Standard Discharge After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.

Kotronias RA, Teitelbaum M, Webb JG, Mylotte D, Barbanti M, Wood DA, Ballantyne B, Osborne A, Solo K, Kwok CS, Mamas MA, Bagur R.

JACC Cardiovasc Interv. 2018 Sep 10;11(17):1759-1771. doi: 10.1016/j.jcin.2018.04.042.

5.

Cardiac resynchronization is pro-arrhythmic in the absence of reverse ventricular remodelling: a systematic review and meta-analysis.

Deif B, Ballantyne B, Almehmadi F, Mikhail M, McIntyre WF, Manlucu J, Yee R, Sapp JL, Roberts JD, Healey JS, Leong-Sit P, Tang AS.

Cardiovasc Res. 2018 Sep 1;114(11):1435-1444. doi: 10.1093/cvr/cvy182.

PMID:
30010807
6.

De novo repeat interruptions are associated with reduced somatic instability and mild or absent clinical features in myotonic dystrophy type 1.

Cumming SA, Hamilton MJ, Robb Y, Gregory H, McWilliam C, Cooper A, Adam B, McGhie J, Hamilton G, Herzyk P, Tschannen MR, Worthey E, Petty R, Ballantyne B; Scottish Myotonic Dystrophy Consortium, Warner J, Farrugia ME, Longman C, Monckton DG.

Eur J Hum Genet. 2018 Nov;26(11):1635-1647. doi: 10.1038/s41431-018-0156-9. Epub 2018 Jul 2.

7.

Unique ECG Findings in Acute Pulmonary Embolism: STE with Reciprocal Changes and Pathologic Q Wave.

Grant-Orser A, Ballantyne B, Haddara W.

Case Rep Crit Care. 2018 Apr 3;2018:7865894. doi: 10.1155/2018/7865894. eCollection 2018.

8.

Vagus nerve injury symptoms after catheter ablation for atrial fibrillation.

Jacobs V, May HT, Crandall BG, Ballantyne B, Chisum B, Johnson D, Graves KG, Cutler M, Day JD, Mallender C, Osborn JS, Weiss JP, Bunch TJ.

Pacing Clin Electrophysiol. 2018 Apr;41(4):389-395. doi: 10.1111/pace.13304. Epub 2018 Mar 30.

PMID:
29435991
9.

Triage des appels de gestion des symptômes avec et sans guides de pratique : étude de cas.

Ballantyne B, Stacey D.

Can Oncol Nurs J. 2016 Jul 1;26(3):209-214. doi: 10.5737/23688076263209214. eCollection 2016 Summer. French. No abstract available.

PMID:
31148710
Free PMC Article
10.

Triaging symptom calls with and without practice guides: A case exemplar.

Ballantyne B, Stacey D.

Can Oncol Nurs J. 2016 Jul 1;26(3):203-208. doi: 10.5737/23688076263203208. eCollection 2016 Summer.

11.

Implementation of Symptom Protocols for Nurses Providing Telephone-Based Cancer Symptom Management: A Comparative Case Study.

Stacey D, Green E, Ballantyne B, Tarasuk J, Skrutkowski M, Carley M, Chapman K, Kuziemsky C, Kolari E, Sabo B, Saucier A, Shaw T, Tardif L, Truant T, Cummings GG, Howell D.

Worldviews Evid Based Nurs. 2016 Dec;13(6):420-431. doi: 10.1111/wvn.12166. Epub 2016 May 31.

12.

Patient and family experiences with accessing telephone cancer treatment symptom support: a descriptive study.

Stacey D, Green E, Ballantyne B, Skrutkowski M, Whynot A, Tardif L, Tarasuk J, Carley M; Pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Team.

Support Care Cancer. 2016 Feb;24(2):893-901. doi: 10.1007/s00520-015-2859-6. Epub 2015 Aug 15.

PMID:
26275766
13.

Access to oncology consultation in a cancer cohort in northeastern Ontario.

Conlon M, Hartman M, Ballantyne B, Aubin N, Meigs M, Knight A.

Curr Oncol. 2015 Apr;22(2):e69-75. doi: 10.3747/co.22.2309.

14.

Training oncology nurses to use remote symptom support protocols: a retrospective pre-/post study.

Stacey D, Skrutkowski M, Carley M, Kolari E, Shaw T, Ballantyne B.

Oncol Nurs Forum. 2015 Mar;42(2):174-82. doi: 10.1188/15.ONF.174-182.

PMID:
25806884
15.

Perceived factors influencing nurses' use of evidence-informed protocols for remote cancer treatment-related symptom management: A mixed methods study.

Stacey D, Carley M, Ballantyne B, Skrutkowski M, Whynot A; Pan-Canadian Oncology Symptom Triage and Remote Support COSTaRS Team.

Eur J Oncol Nurs. 2015 Jun;19(3):268-77. doi: 10.1016/j.ejon.2014.11.002. Epub 2014 Dec 17.

16.

Managing symptoms during cancer treatments: evaluating the implementation of evidence-informed remote support protocols.

Stacey D, Bakker D, Ballantyne B, Chapman K, Cumminger J, Green E, Harrison M, Howell D, Kuziemsky C, MacKenzie T, Sabo B, Skrutkowski M, Syme A, Whynot A.

Implement Sci. 2012 Nov 19;7:110. doi: 10.1186/1748-5908-7-110.

17.

Quadriceps fatigue alters human muscle performance during a novel weight bearing task.

Ballantyne BT, Shields RK.

Med Sci Sports Exerc. 2010 Sep;42(9):1712-22. doi: 10.1249/MSS.0b013e3181d85527.

18.

Triethylene glycol HO(CH2CH2O)3H.

Ballantyne B, Snellings WM.

J Appl Toxicol. 2007 May-Jun;27(3):291-9. Review.

PMID:
17299811
20.
21.

The effect of a single treatment of the Protonics system on lower extremity kinematics during gait and the lateral step up exercise.

McCrory JL, Quick NE, Shapiro R, Ballantyne BT, Davis I.

Gait Posture. 2007 Apr;25(4):544-8. Epub 2006 Aug 2.

PMID:
16887352
22.
23.

Developmental toxicity study with triethylene glycol given by gavage to CD rats and CD-1 mice.

Ballantyne B, Snellings WM.

J Appl Toxicol. 2005 Sep-Oct;25(5):418-26.

PMID:
16092104
24.

Developmental toxicity study with diethylene glycol dosed by gavage to CD rats and CD-1 mice.

Ballantyne B, Snellings WM.

Food Chem Toxicol. 2005 Nov;43(11):1637-46.

PMID:
15979775
25.

The addition of the Protonics brace system to a rehabilitation protocol to address patellofemoral joint syndrome.

Denton J, Willson JD, Ballantyne BT, Davis IS.

J Orthop Sports Phys Ther. 2005 Apr;35(4):210-9.

PMID:
15901122
26.
27.

2-Ethyl-1,3-hexanediol.

Ballantyne B.

J Appl Toxicol. 2005 May-Jun;25(3):248-59. Review. No abstract available.

PMID:
15856531
28.

Bis[2-(dimethylamino)ethyl]ether(CH3)2NCH2CH2OCH2CH2N(CH3)2.

Ballantyne B.

J Appl Toxicol. 2005 May-Jun;25(3):260-9. No abstract available.

PMID:
15856527
29.

Glaucopsia: an occupational ophthalmic hazard.

Ballantyne B.

Toxicol Rev. 2004;23(2):83-90. Review.

PMID:
15578863
30.

Core stability measures as risk factors for lower extremity injury in athletes.

Leetun DT, Ireland ML, Willson JD, Ballantyne BT, Davis IM.

Med Sci Sports Exerc. 2004 Jun;36(6):926-34.

PMID:
15179160
31.

The effect of a single treatment of the Protonics system on biceps femoris and gluteus medius activation during gait and the lateral step up exercise.

McCrory JL, Quick NE, Shapiro R, Ballantyne BT, McClay Davis I.

Gait Posture. 2004 Apr;19(2):148-53.

PMID:
15013503
32.

Hip strength in females with and without patellofemoral pain.

Ireland ML, Willson JD, Ballantyne BT, Davis IM.

J Orthop Sports Phys Ther. 2003 Nov;33(11):671-6.

PMID:
14669962
33.

Percutaneous toxicokinetic and repeated cutaneous contact studies with ethylene glycol monohexyl ether.

Ballantyne B, Jensen CB, Weaver EV.

J Appl Toxicol. 2003 Sep-Oct;23(5):301-14.

PMID:
12975769
34.

Comparison of outcomes between males and females after anterior cruciate ligament reconstruction.

Ott SM, Ireland ML, Ballantyne BT, Willson JD, McClay Davis IS.

Knee Surg Sports Traumatol Arthrosc. 2003 Mar;11(2):75-80. Epub 2003 Feb 22.

PMID:
12664198
35.

Toxicity and pharmacokinetics of 2-(2-dimethylaminoethoxy)ethanol following cutaneous dosing.

Leung HW, Frantz SW, Ballantyne B.

Food Chem Toxicol. 2002 Jul;40(7):1033-40.

PMID:
12065226
36.

Chronic toxicity and oncogenicity study with glutaraldehyde dosed in the drinking water of Fischer 344 rats.

Van Miller JP, Hermansky SJ, Losco PE, Ballantyne B.

Toxicology. 2002 Jun 14;175(1-3):177-89.

PMID:
12049846
37.

Acute effects of the Protonics system on patellofemoral alignment: an MRI study.

Sathe VM, Ireland ML, Ballantyne BT, Quick NE, McClay IS.

Knee Surg Sports Traumatol Arthrosc. 2002 Jan;10(1):44-8. Epub 2001 Oct 17.

PMID:
11819021
38.

Genetic toxicology studies with glutaraldehyde.

Vergnes JS, Ballantyne B.

J Appl Toxicol. 2002 Jan-Feb;22(1):45-60.

PMID:
11807929
39.

In vitro and in vivo genetic toxicology studies with diethylene glycol monohexyl ether.

Ballantyne B, Vergnes JS.

J Appl Toxicol. 2001 Nov-Dec;21(6):449-60.

PMID:
11746191
40.

Subchronic peroral toxicity of triethylene glycol in the Fischer 344 rat.

Van Miller JP, Ballantyne B.

Vet Hum Toxicol. 2001 Oct;43(5):269-76.

PMID:
11577930
41.

A radiographic analysis of the relationship between the size and shape of the intercondylar notch and anterior cruciate ligament injury.

Ireland ML, Ballantyne BT, Little K, McClay IS.

Knee Surg Sports Traumatol Arthrosc. 2001 Jul;9(4):200-5.

PMID:
11522074
42.

The acute toxicity and primary irritancy of glutaraldehyde solutions.

Ballantyne B, Myers RC.

Vet Hum Toxicol. 2001 Aug;43(4):193-202.

PMID:
11474730
43.

2,4-Pentanedione.

Ballantyne B, Cawley TJ.

J Appl Toxicol. 2001 Mar-Apr;21(2):165-71. Review. No abstract available.

PMID:
11288138
44.
45.

Systemic toxicity from repeated cutaneous contact with 2,4-pentanedione.

Ballantyne B.

Vet Hum Toxicol. 2001 Feb;43(1):14-8.

PMID:
11205070
46.

Acute and repeated vapor exposure toxicology of 3-(methylthio)propionaldehyde.

Ballantyne B, Cawley TJ.

Vet Hum Toxicol. 2000 Dec;42(6):330-6.

PMID:
11111937
47.

Two-generation reproduction study by dosing with glutaraldehyde in the drinking water of CD rats.

Neeper-Bradley TL, Ballantyne B.

J Toxicol Environ Health A. 2000 Sep 29;61(2):107-29.

PMID:
11032425
48.

Acute toxicity, primary irritancy, and genetic toxicity studies with 3-(methylthio)propionaldehyde.

Ballantyne B, Myers RC.

Vet Hum Toxicol. 2000 Apr;42(2):77-84.

PMID:
10750170
49.

5-Ethylidene-2-norbornene.

Ballantyne B, Cawley TJ.

J Appl Toxicol. 1999 Jul-Aug;19(4):291-4. Review. No abstract available.

PMID:
10439345
50.

Developmental toxicity evaluation of rats dosed orally or cutaneously with octoxynol-9.

Leung HW, Ballantyne B.

J Appl Toxicol. 1999 Jul-Aug;19(4):267-73.

PMID:
10439341

Supplemental Content

Loading ...
Support Center